Stratton , Adler A Ne HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Assoctn of glycaem wh macrovascular and mrovascular complatns of type 2 dbetes (UKPDS 35): prospecte observatnal study. BMJ. 2000 Aug 12;321(7258):405-12. do 10.1136/bmj.321.7258.405. Eckel RH, Wassef M, Cha A, Sobel B, Barrett E, Kg G, Lopes-Vella M, Reusch J, Ruderman N, Steer G, Vlassara H. Preventn Conference V Dbetes and Cardvascular Dease: Wrg Group : pathogenes of atheroscleros dbetes. Cculatn. 2002 May 7;105(18):e138-43. do 10.1161/01.c.0000013954.65303.c5. No abstract avaable. Cerllo A, Esposo K, PonL, nat MA, Thorpe JE, Testa R, BoemM, Gglno D. Osclatg glucose more deleterus to endothell functn and oxate stress than mean glucose normal and type 2 dbet patnts. Dbetes. 2008 May;57(5):1349-54. do 10.2337/db08-0063. Epub 2008 Feb 25. Monnr L, Colette C. Glycem varby: should we and can we prevent ? Dbetes Care. 2008 Feb;31 Suppl 2:S150-4. do 10.2337/dc08-s241. Monnr L, Mas E, Get C, Mhel F, Vlon L, Crtol JP, Colette C. Actatn of oxate stress by acute glucose fluctuatns compared wh sustaed chron hyperglycem patnts wh type 2 dbetes. JAMA. 2006 Apr 12;295(14):1681-7. do 10.1001/jama.295.14.1681. Monnr L, Colette C, Owens DR. Glycem varby: the thd component of the dysglycem dbetes. portant? How to measure ? J Dbetes ScTechnol. 2008 Nov;2(6):1094-100. do 10.1177/193229680800200618. Patouls D, Papadopoulos C, Stavropoulos K, Zografou Doumas M, Karagnn A. Prognost value of arterl stfness measurements cardvascular dease, dbetes, and s complatns: The potentl role of sodm-glucose co-transporter-2 hors. J Cl Hypertens (Greenwh). 2020 Apr;22(4):562-571. do 10.1111/jch.13831. Epub 2020 Feb 14. Vukov J, Modun D, Bud D, Sutlov D, Salamun Zaja Boban M. Acute, food-duced moderate elevatn of plasma ur ac protects agast hyperox-duced oxate stress and crease arterl stfness healthy humans. Atheroscleros. 2009 Nov;207(1):255-60. do 10.1016/j.atheroscleros.2009.04.012. Epub 2009 Apr 17. Tammen MK, Westerbacka J, Vehkavaara S, YkJarven H. sul therapy proves sul actns on glucose metabolm and aort wave reflectn type 2 dbet patnts. Eur J Cl vest. 2003 Oct;33(10):855-60. do 10.1046/j.1365-2362.2003.01220.x. Gord D, Saraheo M, Tuomangas J, Soro-Paavonen A, Forsblom C, Paavonen K, Steckel-Hamann B, Harjutsalo V, Nolaou L, Pavo Koto V, Groop PH. sul exposure mates the crease of arterl stfness patnts wh type 2 dbetes and albumur: an exploratory analys. Acta Dbetol. 2019 Nov;56(11):1169-1175. do 10.1007/s00592-019-01351-4. Epub 2019 May 22. Aslan Kucuksayan E, Aslan M. Effect of sul analog tn therapy on LDL/HDL subfractn profe and HDL assocted enzymes type 2 dbet patnts. Ls Health D. 2013 Apr 24;12:54. do 10.1186/1476-511X-12-54. Home P, Bartley P, Russell-Jones D, Hanae-Brout H, Heeg JE, Abrams P, Land-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Admtratn of Detem sul Effacy, Safety and Suaby (STEADESS) Study Group. sul detem offers proved glycem control compared wh NPH sul people wh type 1 dbetes: a randomed clal trl. Dbetes Care. 2004 May;27(5):1081-7. do 10.2337/dcare.27.5.1081. Hee T, Mathu C. pact of the mode of protractn of basal sul theraps on the pharmacoket and pharmacodynam properts and resultg clal outcomes. Dbetes Obes Metab. 2017 Jan;19(1):3-12. do 10.1111/dom.12782. Epub 2016 Sep 26. TaldJ, Hadley-Brown M, Lbl A, Haldrup S, Sandberg V, Wolden ML, Rodbard HW. A comparate effecteness study of degludec and sul glarge 300 U/mL sul-nae patnts wh type 2 dbetes. Dbetes Obes Metab. 2019 Apr;21(4):1001-1009. do 10.1111/dom.13616. Epub 2019 Jan 8. Rosenstock J, Cheng A, Rzel R, Bosnyak Z, Devme C, CalAMG, Sber J, Stella P, Wang X, Frs JP, Roussel R, BollGB. More Sars Than Dferences Testg sul Glarge 300 Uns/mL Versus sul Degludec 100 Uns/mL sul-Nae Type 2 Dbetes: The Randomed Head-to-Head BRHT Trl. Dbetes Care. 2018 Oct;41(10):2147-2154. do 10.2337/dc18-0559. Epub 2018 Aug 13. The Differences Between Insulin Glargine U300 and Insulin Degludec U100 in Impact on the Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles in Insulin naïve Patients Suffering From Type Two Diabetes Mellitus